全球同种异体干细胞市场规模、份额及成长分析（按类型、应用、最终用户和地区）- 产业预测（2025-2032）

预计 2023 年全球同种异体干细胞市场规模将达到 2.583 亿美元，从 2024 年的 3.2494 亿美元成长到 2032 年的 20.3822 亿美元，预测期内（2025-2032 年）的复合年增长率为 25.8%。

全球同种异体干细胞市场正经历强劲成长，这得益于慢性病和退化性疾病日益普及的推动。从健康捐赠者身上采集的干细胞为癌症、心血管疾病和自体免疫疾病等疾病提供了一种有希望的治疗方案。作为一种“现成的治疗方法”，干细胞比自体治疗方法具有显着的竞争优势，人们对可扩展且可及的细胞疗法的兴趣日益浓厚，这与再生医学研究的蓬勃发展相吻合。然而，该市场面临免疫排斥和移植物抗宿主疾病 (GvHD) 等挑战，使患者面临免疫力缺乏的风险。此外，复杂且昂贵的製造流程、冗长的监管障碍以及对捐赠细胞可用性的伦理担忧，都对市场扩张构成了重大障碍。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 第二手/一级资讯来源
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

同种异体干细胞市场规模（按类型）及复合年增长率（2025-2032）

• 市场概览
• 间质干细胞（MSCs）
• 造血干细胞（HSC）
• 诱导性多功能干细胞（iPSC）
• 胚胎干细胞（ES细胞）

同种异体干细胞市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 肿瘤学（癌症）
• 心血管疾病
• 整形外科疾病
• 神经系统疾病
• 自体免疫疾病
• 创伤治疗

异体干细胞市场规模（依最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 医院和诊所
• 生物技术和製药公司
• 学术研究机构

同种异体干细胞市场规模，复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Mesoblast Limited（Australia）
• Athersys, Inc.（United States）
• Pluristem Therapeutics Inc.（Israel）
• Osiris Therapeutics（United States）
• Gamida Cell（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（Kite Pharma）（United States）
• Bristol Myers Squibb（Juno Therapeutics）（United States）
• Allogene Therapeutics（United States）
• Fate Therapeutics（United States）
• Century Therapeutics（United States）
• Sana Biotechnology（United States）
• Cynata Therapeutics Limited（Australia）
• Lineage Cell Therapeutics, Inc.（United States）

结论和建议

Global Allogeneic Stem Cells Market size was valued at USD 258.3 million in 2023 and is poised to grow from USD 324.94 million in 2024 to USD 2038.22 million by 2032, growing at a CAGR of 25.8% during the forecast period (2025-2032).

The global allogeneic stem cells market is witnessing robust growth, fueled by the increasing incidence of chronic and degenerative diseases. These stem cells, derived from healthy donors, present promising treatment solutions for conditions such as cancer, cardiovascular issues, and autoimmune disorders. Their ability to function as "off-the-shelf therapies" provides a significant competitive edge over autologous treatments, and rising interest in scalable, accessible cell therapies aligns with the surge in regenerative medicine initiatives. Nevertheless, the market faces challenges, including immune rejection and Graft-versus-Host disease (GvHD), which keep patients at risk of immunocompromise. Additionally, the intricate and costly manufacturing processes, along with lengthy regulatory hurdles and ethical concerns regarding donor cell availability, pose substantial barriers to market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Allogeneic Stem Cells market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Allogeneic Stem Cells Market Segments Analysis

Global Allogeneic Stem Cells Market is segmented by Type, Application, End User and region. Based on Type, the market is segmented into Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs), Induced Pluripotent Stem Cells (iPSCs) and Embryonic Stem Cells (ESCs). Based on Application, the market is segmented into Oncology (Cancer), Cardiovascular Diseases, Orthopaedic Disorders, Neurological Disorders, Autoimmune Diseases and Wound Healing. Based on End User, the market is segmented into Hospitals & Clinics, Biotechnology & Pharmaceutical Companies and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Allogeneic Stem Cells Market

The Global Allogeneic Stem Cells market is significantly driven by the advantages of sourcing stem cells from healthy donors, as opposed to autologous therapies which are reliant on individual patients. Allogeneic stem cells are produced in large quantities, leading to immediate availability for treatment. This bulk manufacturing creates a cost-efficient model that promotes widespread access to cutting-edge therapies across various applications and diseases. By offering an off-the-shelf solution, allogeneic stem cells facilitate quicker and easier implementation of innovative treatments, thereby expanding their potential impact in the healthcare market and enhancing patient care opportunities on a broader scale.

Restraints in the Global Allogeneic Stem Cells Market

A significant challenge in the allogeneic stem cell market is the risk of immune rejection by the recipient's body or the donor cells attacking the recipient's tissue, a condition known as Graft-versus-Host Disease (GVHD). This complication often necessitates the use of immunosuppressive medications, which can lead to substantial side effects and potentially diminish the effectiveness of the treatment. Consequently, the need for ongoing management of these adverse effects can hinder patient compliance and overall treatment outcomes, creating a notable restraint on the market for allogeneic stem cell therapies.

Market Trends of the Global Allogeneic Stem Cells Market

The global allogeneic stem cells market is witnessing a significant shift as researchers focus on the development of hypoimmunogenic "stealth" cells, which are designed to evade rejection by the patient's immune system. Leveraging advanced gene-editing technologies, such as CRISPR, these universal donor cells hold the promise of revolutionizing therapeutic approaches by potentially obviating the need for immunosuppressive drugs. This innovation is anticipated to enhance the safety and efficacy of stem cell therapies, thereby attracting greater investment and interest in clinical applications. Consequently, this trend is likely to propel the growth of the allogeneic stem cells market, paving the way for more accessible treatments.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Allogeneic Stem Cells Market Size by Type & CAGR (2025-2032)

• Market Overview
• Mesenchymal Stem Cells (MSCs)
• Hematopoietic Stem Cells (HSCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Embryonic Stem Cells (ESCs)

Global Allogeneic Stem Cells Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology (Cancer)
• Cardiovascular Diseases
• Orthopaedic Disorders
• Neurological Disorders
• Autoimmune Diseases
• Wound Healing

Global Allogeneic Stem Cells Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes

Global Allogeneic Stem Cells Market Size & CAGR (2025-2032)

• North America (Type, Application, End User)
  • US
  • Canada
• Europe (Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Mesoblast Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athersys, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluristem Therapeutics Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (Kite Pharma) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Juno Therapeutics) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Century Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sana Biotechnology (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations